Pulse Biosciences (NASDAQ:PLSE) Reaches New 52-Week High – Time to Buy?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) reached a new 52-week high on Wednesday . The stock traded as high as $31.70 and last traded at $31.7290, with a volume of 69954 shares traded. The stock had previously closed at $30.26.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PLSE. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a report on Thursday, June 4th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.67.

Pulse Biosciences Trading Down 5.4%

The company has a market cap of $2.15 billion, a P/E ratio of -28.18 and a beta of 1.65. The business has a 50 day moving average price of $26.64 and a 200-day moving average price of $22.03.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. On average, sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Transactions at Pulse Biosciences

In other news, Director Robert W. Duggan acquired 660,233 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $19.69 per share, with a total value of $12,999,987.77. Following the transaction, the director directly owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. The trade was a 1.39% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Paul A. Laviolette acquired 15,000 shares of the stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,000 shares in the company, valued at $295,350. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors have recently bought and sold shares of PLSE. Bank of America Corp DE raised its stake in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after buying an additional 65,884 shares during the period. Cetera Investment Advisers bought a new position in shares of Pulse Biosciences during the 1st quarter worth approximately $387,000. Tudor Investment Corp ET AL bought a new position in shares of Pulse Biosciences during the 4th quarter worth approximately $382,000. Inspire Investing LLC increased its holdings in shares of Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock worth $469,000 after acquiring an additional 8,561 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock worth $291,000 after acquiring an additional 3,991 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.